Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07387926 |
| Title | Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Novartis Pharmaceuticals |
| Indications | |
| Therapies | |
| Age Groups: | adult | child |
| Covered Countries | ISR | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | RECRUITING | Sydney | New South Wales | 2031 | Australia | Details |
| Novartis Investigative Site | RECRUITING | Ramat Gan | 5265601 | Israel | Details | |
| Novartis Investigative Site | RECRUITING | Taipei | 10002 | Taiwan | Details |